NEW YORK / Jun 01, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the following investor conferences in June 2023:
Company executives will take part in a fireside chat at the 2023 Jefferies Healthcare Conference in New York, New York on June 8, 2023. They will answer questions about the company at 9:00 a.m. ET.
Bristol Myers Squibb executives will also participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023, in Dana Point, California. They will answer questions about the company at 8:40 a.m. PT/11:40 a.m. ET.
Investors and the general public are invited to listen to a live webcast of both sessions during their respective times at http://investor.bms.com. An archived edition of each session will be available later the same day it occurs.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$56.81 |
| Daily Change: | -0.33 -0.58 |
| Daily Volume: | 9,262,814 |
| Market Cap: | US$115.320B |
December 23, 2024 December 09, 2024 November 19, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
